Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, John Lenehan et al.|Nature Medicine|2023Cited by 446
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Anna Maria Di Giacomo et al.|The Lancet Oncology|2021Cited by 389
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitorsArielle Elkrief, Bertrand Routy, Layal El Raichani et al.|OncoImmunology|2019Cited by 207
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, Ian R. Watson, LeeAnn Ramsay et al.|Science Immunology|2022Cited by 131